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OBJECTIVES: To study the incidence-based cost of illness
for postmenopausal women newly diagnosed with breast
cancer, and to extrapolate this to a national level.
METHODS: Published data from long term studies de-
scribe the disease history of women diagnosed with breast
cancer. We simulated this history in a state transitional
model, including 5 states (early cancer node negative; early
cancer node positive; local relapse; metastasis, all with fol-
low-up; and death), covering 10 periods of 1 year. To cal-
culate the costs of each state, an analysis of medical
records of 120 patients in different states was organized in
six centers, representative for size and regional distribu-
tion. In each centre, the records of 20 patients with either a
new diagnosis, or a diagnosis of recurrence in early 1997
were randomly selected and an independent physician in-
vestigated the medical resource use up to end 1998. Re-
sulting direct medical costs were calculated from the
health care insurance perspective and applied into the
model, discounting at 3%. Based on national incidence
data, a population-based cost was derived. The model was
validated by comparison of predicted with observed me-
tastasis rates and mortality.
RESULTS: The cumulative 10 year cost per patient 
31,900 Euro (range  10,300–152,400). The average cost
constitutes of 47% hospital, 23% surgery and 20% drug
costs. The majority of costs occur in the year after diagno-
sis and in the year before death. The total 10 year cost for
an absolute incident population  237 Million Euro. The
relative difference between predicted and observed mortal-
ity was 2.6%, and between predicted and observed me-
tastases 3.5%.
CONCLUSIONS: This incidence-based approach identi-
fied the cost of postmenopausal breast cancer over time
and may serve as a baseline against which to assess new in-
terventions in either its prevention or in its early treatment.
ECONOMIC AND OUTCOMES ISSUES OF 
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OBJECTIVES: The objective of this meta-analysis is to as-
sess whether the results from an indirect treatment com-
parison are similar to those from randomized clinical trials
with antipsychotic drugs. A direct and indirect treatment
comparison was conducted on olanzapine and risperidone,
using haloperidol as the control group.
METHODS: Clinical trials comparing olanzapine and ris-
peridone to haloperidol were identified through literature
searches, and were reviewed by four people. Extracted
were changes from baseline to endpoint for the BPRS to-
tal, the PANSS negative, the percentage use of anticholin-
ergic drugs, and the percentage of drop-outs. To conduct
the meta-analysis, the fixed effect model was chosen over
the random effect method. Missing data were estimated
from regression analyses. Safety measures were difficult to
compare since the instruments used were different for the
olanzapine and risperidone trials.
RESULTS: The results reported a similar efficacy between
the two drugs. With the indirect method, differences found
were a BPRS Total Change of 0.97 (1.1; 3.0) and a
PANSS Negative Change of 0.95 (0.23; 2.1). With the
direct method, the results were 1.80 (1.4; 5.0) and 1.10
(0.44; 2.6) for both outcomes, respectively. Results for
the other percentage of patients using anticholinergic
drugs, and the percentage of drop-outs estimated with the
indirect method, tend to favor olanzapine. 19.3% more
patients in the olanzapine group, compared to the risperi-
done group, used no anticholinergic drugs. As for the
drop-out rates, there were no statistically significant differ-
ences between the two treatment groups.
CONCLUSIONS: The comparison of the direct and indi-
rect method using olanzapine and risperidone showed dif-
ferences in results, although the conclusion for efficacy
was the same. Differences may be due to the study dura-
tion. Hence, this method must be used carefully when con-
sidering different study designs.
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OBJECTIVE: Evaluate the doses of olanzapine, risperi-
done, and haloperidol in outpatients with schizophrenia.
METHODS: A 6-month, prospective, comparative, study.
Data were collected by psychiatrists at mental health cen-
ters and other outpatient facilities. The antipsychotic drug,
doses, adverse events, CGI scale scores, and the GAF scale
scores were recorded. Clinical response was defined as a
decrease of at least 2 points on the CGI, with a final CGI
score 	4.
